For Quick Alerts
For Daily Alerts

Suven Life Sciences Q1 net falls 41.8% at Rs 20.23 cr

By Religare

Drug major Suven Life Sciences Ltd reported a decline of 41.8 per cent in its standalone net profit after taxes (PAT) at Rs 20.23 crore for the first quarter ended June 30, 2015, on the back of decline in sales of its contract research and manufacturing services (CRAMS) business.

"The standalone net profit of the drug maker stood at Rs 34.74 crore during the same period a year ago," said Suven Life Sciences Ltd in a filing to the Bombay Stock Exchange.


The standalone total income from operations of the company fell by 28.7 per cent at Rs 100.98 crore during Q1 2015-16, as compared to Rs 141.53 crore during the same period last year.

It spent about Rs 15.9 crore, or 15 per cent, of revenue on research and development.

The company's board has authorized to create an overseas subsidiary with an initial investment of USD 25 million for clinical development and commercialization of Suven pipeline and in-licensed molecules.

Meanwhile, shares of the company ended Friday's trade at Rs 255 apiece, up 2.27 per cent, from previous close on BSE.

Story first published: Monday, August 17, 2015, 9:40 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more